Did you know?
Around 80% of rare conditions arise due to changes in a person's genomic makeup, which can be inherited or arise for the first time in an individual. 🧬
🎙️Hear from mTOR node
@BatemanLab
I am looking for a Research Assistant for a 10 month position in my lab. The RA will support several ongoing projects primarily using Drosophila models but also iPSC/organoid models of rare disease. @KingsIoPPNmy.corehr.com/pls/kclrecruit…
🚀Check out this recent publication from the mTOR Pathway Diseases node - Challenges and opportunities from bench to bedside and the mTOR node tinyurl.com/mTORnode@BatemanLab@CharlotteRTye
We’re delighted to announce a new partnership between Oxford StemTech, @KingsCollegeLon, and MaxWell Biosystems, funded by @Innosuisse.
Many patients with #epilepsy struggle with limited treatment options to manage their seizures effectively. To address this, our collaboration is focused on creating a high-throughput #drugtesting platform using physiologically relevant models.
King’s will provide access to epilepsy patients. By integrating Oxford StemTech’s ReproPlex #iPSC reprogramming technology with MaxWell Biosystems’ advanced MaxTwo HD-#MEA (High-Density Microelectrode Array) System featuring a 24-well plate format, we can simultaneously analyze multiple patient-specific brain assembloids. This approach will provide a unique platform to understand epilepsy better and test potential new treatments with precision.
We are excited to work together on this project and look forward to contributing to advancements in epilepsy research. Please refer to our website for more details 👉mxwbio.com/company/projects-…
Stay tuned for updates!
🧲Ready to make a real difference in research and advocacy?
📡By listening, sharing, and working together, we can better address the challenges faced in rare disease research
🌟Join us for our free webinar on Introduction to Co-Production!
Register now🔗tinyurl.com/yy2af665
📢Registrations Now Open📢
🌟Join us for our 2nd Hybrid Annual Conference!🌟
💊inspiring keynote speakers 🪩lively panel discussions💥connect with others who are just as passionate about driving progress in rare disease research!
🔗tinyurl.com/RDRUKConf
Our lab's latest study, spearheaded by a fantastic colleague, Colleen, reveals that the blood glucose-lowering effect of metformin requires the inhibition of mitochondrial ETC complex I. science.org/doi/10.1126/scia….
An insightful focus by Prof. Doug Green: bit.ly/41Hc4fX
We had a brilliant time attending the mTOR Pathway Diseases node patient organisation workshop last week. Great to hear exciting updates from the #Research team and a great opportunity to connect with other patient orgs @BatemanLab@CharlotteRTye
A snippet from our day. I feel privileged to lead #PPI for the mTOR node and to learn so much from our patient organisation partners and lived experience experts- thank you for giving your time and helping our research grow. Watch this space! @KingsIoPPN
We have funding from the MND Association for a PhD studentship, starting in September 2025, if interested please see
@FindAPhDfindaphd.com/phds/projectdet…
A huge thank you to @BatemanLab from King's College London, who gave a fantastic seminar on the 'Mechanistic insight into the role of mTOR signalling in rare neurological diseases' today as part of our lunchtime seminar series.